500 patients to help unlock secrets of rare histiocytosis disorders

NCT ID NCT07157683

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study will collect blood, saliva, urine, and stool samples from 500 adults with systemic histiocytosis—a group of rare inflammatory disorders. Researchers aim to identify biomarkers that could improve diagnosis, predict disease progression, and enable less invasive monitoring. The study does not test any treatment but may guide future targeted therapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to better diagnostic tools and less invasive monitoring methods for systemic histiocytosis.

What could go wrong

This is an observational study that collects samples only—it does not test a treatment. The findings may not lead to immediate clinical changes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LANGERHANS CELL HISTIOCYTOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Erdheim-Chester disease histiocytosis Langerhans cell histiocytosis sinus histiocytosis with massive lymphadenopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Internal Medicine Department 2 at Pitié-Salpêtrière Hospital

    Paris, 75013, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••